NEW YORK, Jan. 23, 2020 Oramed Pharmaceuticals Inc.
(NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage
pharmaceutical company focused on the development of oral drug
delivery systems, announced today the addition of Dr. Alexander Fleming to its Scientific Advisory
Board.
Dr. Fleming is Founder and Executive Chairman of Kinexum. Dr.
Fleming previously held various positions at the U.S. Food and Drug
Administration in which he was responsible for the therapeutic
areas of diabetes and other metabolic and endocrine disorders. He
led reviews of landmark approvals, including metformin and the
first statin, insulin analog, PPAR-agonist, and growth hormone for
non-GH deficiency indications. Dr. Fleming oversaw clinical review
of the earliest biotech products, including human insulin. Dr.
Fleming also helped to shape FDA policies and practices related to
therapeutic review and regulatory communication.
"We are honored and extremely fortunate to welcome Dr. Fleming
to our Scientific Advisory Board. His expansive knowledge of
diabetes and clinical development will be invaluable as our oral
ORMD-0801 insulin program continues to progress towards our vision
of becoming the first oral insulin therapy available to physicians
and their patients battling diabetes," said Nadav Kidron, CEO of Oramed.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a platform technology pioneer in
the field of oral delivery solutions for drugs currently delivered
via injection. Established in 2006, with offices in New
York and Israel, Oramed has developed a novel Protein
Oral Delivery (POD™) technology that is based on more
than 30 years of research by scientists
at Jerusalem's Hadassah Medical Center. Oramed is seeking
to revolutionize the treatment of diabetes through its proprietary
lead candidate, ORMD-0801, which has the potential to be the
first commercial oral insulin capsule for the treatment
of Type 2 and Type 1 diabetes. The Company has completed
multiple Phase II clinical trials under an Investigational New Drug
application with the U.S. Food and Drug Administration. In
addition, Oramed is developing an oral GLP-1 (Glucagon-like
peptide-1) analog capsule, ORMD-0901.
For more information, please visit www.oramed.com.
Forward-looking statements: This press release
contains forward-looking statements. For example, we are using
forward-looking statements when we discuss the potential of
ORMD-0801 to be the first commercial oral insulin capsule for the
treatment of diabetes or revolutionizing the treatment of diabetes
with our products. In addition, historic results of scientific
research and clinical trials do not guarantee that the conclusions
of future research or trials will suggest identical or even similar
conclusions. These forward-looking statements are based on the
current expectations of the management of Oramed only, and are
subject to a number of factors and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements, including the risks and uncertainties
related to the progress, timing, cost, and results of clinical
trials and product development programs; difficulties or delays in
obtaining regulatory approval or patent protection for our product
candidates; competition from other pharmaceutical or biotechnology
companies; and our ability to obtain additional funding required to
conduct our research, development and commercialization activities.
In addition, the following factors, among others, could cause
actual results to differ materially from those described in the
forward-looking statements: changes in technology and market
requirements; delays or obstacles in launching our clinical trials;
changes in legislation; inability to timely develop and introduce
new technologies, products and applications; lack of validation of
our technology as we progress further and lack of acceptance of our
methods by the scientific community; inability to retain or attract
key employees whose knowledge is essential to the development of
our products; unforeseen scientific difficulties that may develop
with our process; greater cost of final product than anticipated;
loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally
good results in real settings; our patents may not be sufficient;
and finally that products may harm recipients, all of which could
cause the actual results or performance of Oramed to differ
materially from those contemplated in such forward-looking
statements. Except as otherwise required by law, Oramed undertakes
no obligation to publicly release any revisions to these
forward-looking statements to reflect events or circumstances after
the date hereof or to reflect the occurrence of unanticipated
events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed's
reports filed from time to time with the Securities and
Exchange Commission.
Company Contact
Oramed Pharmaceuticals
Estee Yaari
+1-844-9-ORAMED
Email: estee@oramed.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/oramed-elects-dr-alexander-fleming-to-scientific-advisory-board-300992014.html
SOURCE Oramed Pharmaceuticals Inc.